| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.
|
J Clin Oncol
|
2005
|
8.08
|
|
2
|
INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy.
|
J Clin Oncol
|
2002
|
6.74
|
|
3
|
Small-cell carcinomas of the gastrointestinal tract: a review.
|
J Clin Oncol
|
2004
|
3.08
|
|
4
|
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.
|
J Clin Oncol
|
2006
|
3.00
|
|
5
|
Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113.
|
J Clin Oncol
|
2008
|
2.07
|
|
6
|
Molecular classification of gastric cancer: a new paradigm.
|
Clin Cancer Res
|
2011
|
2.00
|
|
7
|
Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease.
|
J Natl Compr Canc Netw
|
2010
|
1.85
|
|
8
|
Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer?
|
Ann Surg Oncol
|
2007
|
1.84
|
|
9
|
Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.
|
J Clin Oncol
|
2005
|
1.82
|
|
10
|
Advanced gastric cancer--slow but steady progress.
|
Cancer Treat Rev
|
2010
|
1.79
|
|
11
|
Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.
|
J Clin Oncol
|
2015
|
1.56
|
|
12
|
Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer.
|
Cancer
|
2011
|
1.53
|
|
13
|
Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease.
|
Ann Surg Oncol
|
2002
|
1.50
|
|
14
|
An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions.
|
Oncologist
|
2011
|
1.44
|
|
15
|
MET expression and amplification in patients with localized gastric cancer.
|
Cancer Epidemiol Biomarkers Prev
|
2011
|
1.42
|
|
16
|
Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma.
|
J Clin Oncol
|
2010
|
1.37
|
|
17
|
A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol.
|
Clin Cancer Res
|
2005
|
1.31
|
|
18
|
Small cell carcinomas of the gastrointestinal tract: clinicopathological features and treatment approach.
|
Semin Oncol
|
2007
|
1.23
|
|
19
|
Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy.
|
J Clin Oncol
|
2005
|
1.18
|
|
20
|
A randomized controlled trial of a cardiopulmonary resuscitation video in advance care planning for progressive pancreas and hepatobiliary cancer patients.
|
J Palliat Med
|
2013
|
1.14
|
|
21
|
Targeted therapies for esophageal cancer.
|
Oncologist
|
2005
|
1.11
|
|
22
|
Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer.
|
J Clin Oncol
|
2003
|
1.07
|
|
23
|
Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy.
|
J Clin Oncol
|
2004
|
1.05
|
|
24
|
Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer.
|
Cancer
|
2011
|
1.05
|
|
25
|
Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer.
|
Cancer
|
2011
|
1.01
|
|
26
|
Pneumatosis intestinalis: a variant of bevacizumab related perforation possibly associated with chemotherapy related GI toxicity.
|
Invest New Drugs
|
2007
|
1.01
|
|
27
|
Endoscopic ultrasound can improve the selection for laparoscopy in patients with localized gastric cancer.
|
J Am Coll Surg
|
2008
|
0.98
|
|
28
|
A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma.
|
Invest New Drugs
|
2010
|
0.95
|
|
29
|
A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer.
|
Cancer
|
2012
|
0.93
|
|
30
|
Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine.
|
Am J Clin Oncol
|
2011
|
0.92
|
|
31
|
A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: initial results.
|
J Thorac Cardiovasc Surg
|
2002
|
0.92
|
|
32
|
Combined modality therapy of esophageal cancer: changes in the standard of care?
|
Ann Surg Oncol
|
2004
|
0.91
|
|
33
|
Prognostic significance of targetable angiogenic and growth factors in patients undergoing resection for gastric and gastroesophageal junction cancers.
|
Ann Surg Oncol
|
2013
|
0.90
|
|
34
|
A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer.
|
Pancreatology
|
2009
|
0.90
|
|
35
|
Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer.
|
Cancer Chemother Pharmacol
|
2008
|
0.89
|
|
36
|
Combined modality therapy in esophageal cancer: the Memorial experience.
|
Semin Surg Oncol
|
2003
|
0.84
|
|
37
|
Perineural invasion after preoperative chemotherapy predicts poor survival in patients with locally advanced gastric cancer: gene expression analysis with pathologic validation.
|
Am J Clin Oncol
|
2009
|
0.83
|
|
38
|
Genomic dysregulation in gastric tumors.
|
J Surg Oncol
|
2012
|
0.82
|
|
39
|
Phase II trial of 96-hour paclitaxel in previously treated patients with advanced esophageal cancer.
|
Cancer Invest
|
2003
|
0.81
|
|
40
|
Phase II trial of cetuximab plus cisplatin and irinotecan in patients with cisplatin and irinotecan-refractory metastatic esophagogastric cancer.
|
Am J Clin Oncol
|
2014
|
0.77
|
|
41
|
A young woman with liver cancer.
|
Gastrointest Cancer Res
|
2013
|
0.76
|
|
42
|
Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer.
|
Invest New Drugs
|
2008
|
0.75
|
|
43
|
A case of advanced gastric cancer.
|
Gastrointest Cancer Res
|
2012
|
0.75
|
|
44
|
A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers.
|
Am J Clin Oncol
|
2005
|
0.75
|
|
45
|
Neoadjuvant Therapy in Clinical Stage II Pancreatic Adenocarcinoma.
|
Gastrointest Cancer Res
|
2012
|
0.75
|
|
46
|
The Quality of Quality-of-Life and Cost-Effectiveness Analyses.
|
Gastrointest Cancer Res
|
2008
|
0.75
|
|
47
|
A 72-year-old man with duodenal adenocarcinoma.
|
Gastrointest Cancer Res
|
2012
|
0.75
|
|
48
|
A man with Klinefelter's syndrome and new abdominal distension: a discussion of evaluation and management.
|
J Gastrointest Cancer
|
2012
|
0.75
|
|
49
|
Combined modality therapy in pancreatic adenocarcinoma: review and updates on a controversial issue.
|
Curr Pharm Des
|
2014
|
0.75
|
|
50
|
Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors.
|
Cancer Invest
|
2009
|
0.75
|